Burning Rock Biotech Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yusheng Han

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	16.5%
Permanencia media de la dirección	8.1yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

Mar 25

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Feb 01

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jul 12

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Apr 28

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Dec 23

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Sep 20

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Aug 31

CEO

Yusheng Han (44 yo)

no data

Permanencia

Mr. Yusheng Han is the Founder, Chairman and chief executive officer of Burning Rock Biotech Limited. Mr. Han has 16 year of experience in life science. From June 2011 to November 2013, he was an associate...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yusheng Han	Founder	no data	sin datos	16.46% CN¥ 13.2m
Jinxiang Li	CFO, Compliance Officer & Director	5.3yrs	sin datos	sin datos
Zhihong Zhang	CTO & Director	8.1yrs	sin datos	sin datos
Hao Liu	Senior Advisor	8.7yrs	sin datos	sin datos

8.1yrs

Permanencia media

45.5yo

Promedio de edad

Equipo directivo experimentado: BNREl equipo directivo de la empresa es veterano y experimentado (7.8 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yusheng Han	Founder	no data	sin datos	16.46% CN¥ 13.2m
Jinxiang Li	CFO, Compliance Officer & Director	4.3yrs	sin datos	sin datos
Zhihong Zhang	CTO & Director	less than a year	sin datos	sin datos
Feng Deng	Director	7.7yrs	sin datos	sin datos
Gang Lu	Director	9.8yrs	sin datos	sin datos
Wendy Hayes	Independent Director	3.8yrs	sin datos	sin datos
Min-Jui Shen	Independent Director	3.8yrs	sin datos	sin datos
Licen Lisa Xu	Independent Director	1.8yrs	sin datos	sin datos

3.8yrs

Permanencia media

51.5yo

Promedio de edad

Junta con experiencia: La junta directiva de BNR se considera experimentada (3.5 años de antigüedad promedio).

Burning Rock Biotech Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Burning Rock Biotech Limited, Annual General Meeting, Dec 20, 2023

Burning Rock Biotech Limited Announces Management Changes, Effective June 30, 2023

Less than half of directors are independent

Burning Rock Biotech Limited, Annual General Meeting, Sep 08, 2022

Burning Rock Biotech Limited Announces Board Changes

Burning Rock Announces Changes to Board Composition

Recent updates

Full year 2023 earnings released: CN¥6.38 loss per share (vs CN¥9.35 loss in FY 2022)

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

New minor risk - Share price stability

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

New major risk - Financial position

Burning Rock Announces Receipt of Notification from NASDAQ

Third quarter 2023 earnings released: CN¥1.71 loss per share (vs CN¥2.23 loss in 3Q 2022)

Burning Rock Biotech Limited, Annual General Meeting, Dec 20, 2023

Burning Rock Biotech Limited to Report Q3, 2023 Results on Nov 30, 2023

Burning Rock Biotech Limited Receives Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Second quarter 2023 earnings released: CN¥1.54 loss per share (vs CN¥2.50 loss in 2Q 2022)

New minor risk - Share price stability

Burning Rock Biotech Limited to Report Q2, 2023 Results on Aug 31, 2023

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Burning Rock Biotech Limited Announces Management Changes, Effective June 30, 2023

Burning Rock Biotech Limited Reiterates Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: CN¥1.81 loss per share (vs CN¥2.50 loss in 1Q 2022)

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Burning Rock Biotech Limited Revises Revenue Guidance for Full Year of 2022

Burning Rock Biotech Limited Revises Revenue Guidance for Full Year of 2022

Burning Rock Received FDA Breakthrough Device Designation for Its Overc(Tm) Multi-Cancer Detection Blood Test

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Consensus revenue estimates fall by 13%

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Burning Rock Biotech Limited Provides Earnings Guidance for the Fourth Quarter and Year of 2022

Less than half of directors are independent

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Burning Rock Biotech Limited to Report Q3, 2022 Results on Nov 16, 2022

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Burning Rock Biotech Limited Provides Revenue Guidance for the Fiscal Year 2022

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Burning Rock Biotech Limited to Report Q2, 2022 Results on Aug 31, 2022

Burning Rock Biotech Limited, Annual General Meeting, Sep 08, 2022

Consensus forecasts updated

Burning Rock Biotech Limited Announces Board Changes

Burning Rock Biotech Limited Launches Prospective Interventional Validation Study on Multi-Cancer Early Detection - the PREVENT Study

Burning Rock Announces Changes to Board Composition

Burning Rock Biotech Limited (NasdaqGM:BNR) announces an Equity Buyback for $10 million worth of its shares.

Burning Rock Biotech Limited Presents Latest Clinical Data from Thunder Study At 2022 ASCO Annual Meeting

Burning Rock Localizes As Investors Grow Impatient

First quarter 2022 earnings: Revenues miss analyst expectations

Burning Rock Biotech Limited Provides Revenue Guidance for the Full Year 2022

Burning Rock Biotech Limited to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus EPS estimates fall by 219%

COO & Director notifies of intention to sell stock

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Burning Rock Biotech Limited to Report Q4, 2021 Results on Mar 22, 2022

Burning Rock Biotech Limited Provides Revenue Guidance for 2021

Third quarter 2021 earnings released

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Second quarter 2021 earnings released: CN¥2.33 loss per share (vs CN¥2.68 loss in 2Q 2020)

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

COO & Director notifies of intention to sell stock

First quarter 2021 earnings released: CN¥1.65 loss per share (vs CN¥3.15 loss in 1Q 2020)

Burning Rock Biotech Limited Reiterates Earnings Guidance for the Full Year 2021

Burning Rock Announces the Launch of China’S First Prospective Pan-Cancer Multi-Omics Early Detection Study

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

COO & Director notifies of intention to sell stock

Full year 2020 earnings released: CN¥6.88 loss per share (vs CN¥14.23 loss in FY 2019)

Revenue and earnings beat expectations

New 90-day high: US$39.58

Burning Rock Biotech Limited to Report Q4, 2020 Results on Mar 11, 2021